Zepp Health Corp ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$0.03next fiscal year
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Growth (YoY) Quarterly3,380.0%Target: Double-digit growth sustained above 20%
Gross Margin Quarterly3,770.0%Target: 40.0% or higher
Adjusted Operating Loss Quarterly-16.3Target: Breakeven to positive operating income
Watch Items
- HYROX Global Exclusive Wearable Partnership ExecutionTrigger: Slower-than-expected adoption of Amazfit devices within the HYROX365 ecosystem (gyms, coaches, and athlete communities)Action: Re-evaluate marketing spend efficiency and adjust localized promotional strategies to drive conversion.
- Gross Margin Compression from Component CostsTrigger: Gross margin falling below 35% due to rising memory component costs or supply chain tariffsAction: Optimize product mix toward premium lines (e.g., T-Rex Ultra 2, Active 3 Premium) and renegotiate supplier contracts.
- Operating Expense and Cash Burn RateTrigger: Cash and restricted cash falling below $80 million (from $103.2 million in Q1 2026)Action: Implement strict cost-control measures on R&D and SG&A, and slow down non-essential marketing campaigns.
Research as of 19 Jun 2026